FerMetaFix

Fermenting a Healthier Future Microbiome-Inspired Foods for Metabolic Health Obesity and related conditions like diabetes and heart disease are increasing rapidly worldwide, placing a heavy burden on people’s health and healthcare systems. Current medicines can help but they are often costly, have side effects, and remain out of reach for many. At FermBiosis we started […]

Athero-Screen

Despite effective lipid-lowering therapies, patients remain at risk of cardiovascular disease. By 2030, cardiovascular disease (CVD) is expected to affect about 41% of the Western population. This increase will significantly raise healthcare costs, with U.S. expenditures on CVD projected to triple between 2010 and 2030. Many CVD drugs fail in clinical trials due to a […]

ENRICH-SARCOMA

Sarcomas are soft tissue tumors with limited treatment options, which often include radiation therapy. For some sarcomas, the benefit of radiation is limited, and enhancing its effect could improve patient outcomes. Our research has focused on radiosensitization: increasing the sensitivity of tumors to radiation. We do this via administration of drugs that enrich tumor cells […]

sideroFORCE

Each year, around 7.7 million deaths are linked to bacterial infections, with 4.95 million caused by drug-resistant pathogens. Indeed, antimicrobial resistance undermines the benefits of effective antibiotics, becoming a significant barrier towards achieving the Sustainable Development Goals related to health and poverty alleviation. Although it is of eminent importance to reduce the misuse and overuse […]

tRNA for CMT

Charcot-Marie-Tooth (CMT) disease is a common inherited condition that causes progressive muscle weakness, loss of sensation, and disability. CMT disease type 2D, one of the most severe forms of the disease, is caused by mutations that result in dysfunctional glycyl-tRNA synthetase. Millions of CMT patients worldwide currently face limited treatment options that only manage symptoms […]

Dual Tumor Targeting

Immunotherapy using antibodies targeting tumors has led to important clinical advances, yet only 15-20% of all cancer patients respond to immunotherapy. Thus, there is urgent need to increase the efficacy for immunotherapies and enhance anti-tumor responses. This is exemplified by hematological malignancies including diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), two common and […]

MycoSafe

Globally, 20% of all food and feed — including beverages — is lost to fungal spoilage, while multi-drug resistance in fungal pathogens continues to rise. Current preservation measures rely on energy-intensive processes like pasteurization, or chemical additives such as sulfites and benzoates which are known allergens. Increasing demand for clean-label products and the EU’s push […]

GlycoMASH

GlycoMASH aims to develop a blood test that can detect liver damage before it becomes life-threatening. Liver fibrosis, often observed in fatty liver disease, progresses silently and affects millions globally. People with type 2 diabetes (T2D) are especially vulnerable, of which 65% have fatty liver disease and around 15% progress to advanced liver fibrosis. Current […]

Targeting RNA Dicing

Modular Therapeutics is addressing one of the biggest challenges in medicine: many patients do not respond to existing treatments because their disease is driven by unique molecular changes that current drugs cannot target, often due to an insufficient understanding of the biological impact of these mutations. Our innovation is based on a newly discovered biological […]

Detecting Parkinson

Parkinson’s disease (PD) affects about 10 million people worldwide, and cases are expected to double by 2050. Yet there is still no cure. Because we lack objective tools to monitor disease biology, it is difficult to assess new treatments, and diagnosis often arrives after irreversible brain damage has occurred. Our answer to this problem is […]